New mpox vaccine trial launches in congo – could protect thousands
NCT ID NCT07253675
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests a new vaccine called MVA-SIBP to see if it is safe and helps the body fight mpox (monkeypox). About 180 people in the Democratic Republic of the Congo will take part, including adults, teenagers, and children. Half will get the vaccine and half a placebo, and researchers will monitor side effects and measure immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.